Product
Comirnaty Omicron XBB1.5
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to Assess the Safety and Immunogenicity of a Booster Vaccination With an Adapted Recombinant Protein RBD Fusion Homodimer Candidate Against SARS-CoV-2, in Adults Vaccinated Against COVID-19Status: Active (not recruiting), Estimated PCD: 2024-06-01